Skip to main content


Table 1 Sponsor drug manufacturers subject to expanded access campaigns/petitions

From: Going “social” to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access

Name of sponsor Size of companya Publicly traded? (Yes/No) Number of requestsb
BioMarin Pharmaceutical Inc. Large Yes (NASDAQ Stock Market: BMRN) 1
Bayer AG Large Yes (Frankfurt Stock Exchange: BAYN) 1
Bristol-Meyers Squibb Large Yes (New York Stock Exchange: BMY) 5
Chimerix Inc. Small Yes (NASDAQ Stock Market: CMRX) 1
CureTech Ltd. Small No 1
Eli Lilly and Company Large Yes (New York Stock Exchange: LLY) 1
Genentech Inc. (wholly owned subsidiary of F. Hoffmann-La Roche) Large Yes (SIX Swiss Exchange: ROG; OTCQX: RHHBY) 4
ISIS Pharmaceuticals Inc. Small Yes (NASDAQ Stock Market: ISIS) 1
MedImmune, LLC (wholly owned subsidiary of AstraZeneca) Large Yes (London Stock Exchange, OMX, New York Stock Exchange: AZN) 1
Merck & Co., Inc. Large Yes (New York Stock Exchange: MRK) 8
Pfizer Inc. Large Yes (New York Stock Exchange: PFE) 1
Pharmacyclics LLC Large Yes (NASDAQ Stock Market: PCYC) 1
Shire Plc Large Yes (London Stock Exchange: SHP; NASDAQ Stock Market: SHPG) 1
Total number of firms: 13   Total number of requests: 27
  1. aBusinesses classified as small (<500 employees) according to the U.S. Small Business Administration (under NAICS Association classification 541711, Research and Development in Biotechnology); btotal number of requests equal more than the number of cases reviewed (23), because several patients requested access from more than one sponsor